4.45
前日終値:
$4.265
開ける:
$4.3
24時間の取引高:
526.58K
Relative Volume:
0.48
時価総額:
$303.35M
収益:
-
当期純損益:
$-27.03M
株価収益率:
-7.9464
EPS:
-0.56
ネットキャッシュフロー:
$-23.97M
1週間 パフォーマンス:
+2.30%
1か月 パフォーマンス:
+12.37%
6か月 パフォーマンス:
-14.75%
1年 パフォーマンス:
+104.13%
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
名前
Corvus Pharmaceuticals Inc
セクター
電話
(650) 900-4520
住所
863 MITTEN ROAD, BURLINGAME, CA
CRVS を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
CRVS
Corvus Pharmaceuticals Inc
|
4.45 | 335.45M | 0 | -27.03M | -23.97M | -0.56 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-01-02 | 開始されました | H.C. Wainwright | Buy |
2023-08-18 | 開始されました | Oppenheimer | Outperform |
2021-12-01 | 再開されました | Jefferies | Buy |
2021-05-27 | 開始されました | Cantor Fitzgerald | Overweight |
2021-02-10 | ダウングレード | Mizuho | Buy → Neutral |
2019-09-12 | 開始されました | Mizuho | Buy |
2019-05-29 | 開始されました | ROTH Capital | Buy |
2017-08-24 | アップグレード | Credit Suisse | Underperform → Neutral |
2017-05-01 | ダウングレード | Credit Suisse | Neutral → Underperform |
2016-04-18 | 開始されました | Credit Suisse | Outperform |
2016-04-18 | 開始されました | Guggenheim | Buy |
すべてを表示
Corvus Pharmaceuticals Inc (CRVS) 最新ニュース
Corvus Pharmaceuticals Inc. Stock Analysis and ForecastMarket-leading growth rates - Autocar Professional
What analysts say about Corvus Pharmaceuticals Inc. stockExplosive trading growth - jammulinksnews.com
What drives Corvus Pharmaceuticals Inc. stock priceTremendous growth opportunities - Jammu Links News
Is Corvus Pharmaceuticals Inc. a good long term investmentRapidly expanding wealth - jammulinksnews.com
Why Corvus Pharmaceuticals Inc. stock attracts strong analyst attentionReal Time Alert Service - Newser
What makes Corvus Pharmaceuticals Inc. stock price move sharplyDouble Your Capital Alerts - Newser
How Corvus Pharmaceuticals Inc. stock performs during market volatilityDaily Breakout Picks - Newser
Corvus 'Undervalued' Following Atopic Dermatitis Data From Apogee, Mizuho Securities Says - MarketScreener
Corvus Pharmaceuticals’ Promising Study on Soquelitinib for Atopic Dermatitis - TipRanks
Corvus Pharmaceuticals: Insider Confidence and Clinical Catalysts Fueling Growth - AInvest
OrbiMed Advisors sells Corvus Pharma (CRVS) shares worth $4.89 million By Investing.com - Investing.com Canada
Corvus Pharmaceuticals, Inc.(NasdaqGM: CRVS) added to Russell 3000 Index - MarketScreener
Corvus Pharmaceuticals (CRVS) Gains China Approval for Soquelitinib Trial | CRVS Stock News - GuruFocus
Major Breakthrough: Corvus Expands Atopic Dermatitis Drug Development into Chinese Market with New Trial Approval - Stock Titan
Financial Metrics Exploration: Understanding Corvus Pharmaceuticals Inc (CRVS) Through Ratios - DWinneX
Corvus Pharmaceuticals: Multiple Opportunities, But Plenty Of Risk - Seeking Alpha
Corvus Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Breakthrough Systemic Sclerosis Treatment Shows Promise in Top EULAR Study | CRVS Stock News - Stock Titan
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Corvus reports promising interim data on atopic dermatitis drug By Investing.com - Investing.com South Africa
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - Nasdaq
Corvus Pharmaceuticals Reports 'Clinically Meaningful' Itch Reduction in Latest Phase 1 Atopic Dermatitis Drug Trial Results - MarketScreener
Corvus reports promising interim data on atopic dermatitis drug - Investing.com Australia
Corvus Pharmaceuticals (CRVS) Reports Promising Results for Atopic Dermatitis Treatment | CRVS Stock News - GuruFocus
Corvus Pharmaceuticals Announces Full Data From Cohort 3 Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis - marketscreener.com
Corvus Pharmaceuticals Announces Full Data from Cohort 3 - GlobeNewswire
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Exclusive: Corvus Pharmaceuticals Reveals Latest Pipeline Progress at Major Jefferies Healthcare Conference - Stock Titan
Corvus Pharmaceuticals targets expanded soquelitinib trials with Q4 2025 results expected - MSN
CRVS: Mizuho Adjusts Price Target for Corvus Pharma | CRVS Stock News - GuruFocus
Corvus Pharmaceuticals (CRVS) Target Price Adjusted Amid Positiv - GuruFocus
Corvus Pharmaceuticals (CRVS) Target Price Adjusted Amid Positive Drug Data | CRVS Stock News - GuruFocus
Mizuho cuts Corvus Pharmaceuticals target to $11, keeps rating By Investing.com - Investing.com India
Mizuho Adjusts Price Target on Corvus Pharmaceuticals to $11 From $12, Maintains Outperform Rating - marketscreener.com
Mizuho cuts Corvus Pharmaceuticals target to $11, keeps rating - Investing.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded by StockNews.com to Hold Rating - Defense World
Corvus Pharmaceuticals (CRVS) Sees Increased Investor Interest A - GuruFocus
Corvus Pharmaceuticals (CRVS) Sees Notable Increase in Borrow Ra - GuruFocus
Spotlight On Top Penny Stocks For May 2025 - simplywall.st
Corvus Pharmaceuticals Inc (CRVS) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):